Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
This study aimed at estimating the health and economic outcomes of universal infant vaccination with seven-valent pneumococcal conjugate vaccine (PCV-7) in Italy. A Markov model simulated lifetime evolution of a birth cohort (538,138 children): universal vaccination would avert 769 invasive infections, 18 deaths and 1323 life years. At base-case analysis, universal three-dose vaccination would cost euro 26,449 (95% CI: 1975-62,075) and euro 38,286 (95% CI: 22,164-70,801) per life year-saved in the societal and the NHS perspective, respectively. In the hypothesis of a 5-year long protection period, vaccination would cost euro 32,694 and euro 43,115 per life-year saved. Considering yearly incidence of invasive pneumococcal disease reported for Veneto and Sardinia regions, PCV-7 vaccination would result highly cost-effective determining a cost of euro 10,479 and euro 16,890 per life year-save in the NHS and the societal perspective, respectively.
Marchetti
M
M
Laboratory of Medical Epidemiology, IRCCS Policlinico San Matteo, viale Golgi 19, 27100 Pavia, Italy. marchettim@smatteo.pv.it
Colombo
G L
GL
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D007223:Infant; D007558:Italy / Q000453:epidemiology; D018803:Models, Economic; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000191:economics*; D014611:Vaccination / Q000191:economics; D018074:Vaccines, Conjugate / Q000191:economics
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate